keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/29345146/quantitative-contrast-enhanced-ultrasound-for-monitoring-vedolizumab-therapy-in-inflammatory-bowel-disease-patients-a-pilot-study
#1
Ruediger S Goertz, Daniel Klett, Dane Wildner, Raja Atreya, Markus F Neurath, Deike Strobel
Background Microvascularization of the bowel wall can be visualized and quantified non-invasively by software-assisted analysis of derived time-intensity curves. Purpose To perform software-based quantification of bowel wall perfusion using quantitative contrast-enhanced ultrasound (CEUS) according to clinical response in patients with inflammatory bowel disease treated with vedolizumab. Material and Methods In a prospective study, in 18 out of 34 patients, high-frequency ultrasound of bowel wall thickness using color Doppler flow combined with CEUS was performed at baseline and after 14 weeks of treatment with vedolizumab...
January 1, 2018: Acta Radiologica
https://www.readbyqxmd.com/read/29311733/pulmonary-manifestation-of-crohn-s-disease-developed-under-treatment-with-vedolizumab
#2
Donata Lissner, Rainer Glauben, Kristina Allers, Elena Sonnenberg, Christoph Loddenkemper, Thomas Schneider, Britta Siegmund
No abstract text is available yet for this article.
January 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29258369/high-treatment-persistence-rate-and-significant-endoscopic-healing-among-real-life-patients-treated-with-vedolizumab-a-finnish-nationwide-inflammatory-bowel-disease-cohort-study-finvedo
#3
Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen, Taina Sipponen
OBJECTIVES: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, therefore, it is important to demonstrate effectiveness in real-life clinical practice. We set out to assess real-world treatment outcomes of vedolizumab in a nationwide cohort of treatment refractory Finnish Crohn's disease (CD) and ulcerative colitis (UC) patients...
December 19, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29250803/impact-of-vedolizumab-therapy-on-extra-intestinal-manifestations-in-patients-with-inflammatory-bowel-disease-a-multicentre-cohort-study-nested-in-the-observ-ibd-cohort
#4
S Tadbiri, L Peyrin-Biroulet, M Serrero, J Filippi, B Pariente, X Roblin, A Buisson, C Stefanescu, C Trang-Poisson, R Altwegg, P Marteau, T Vaysse, A Bourrier, S Nancey, D Laharie, M Allez, G Savoye, C Gilletta, C Gagniere, L Vuitton, S Viennot, A Aubourg, A-L Pelletier, G Bouguen, V Abitbol, M Fumery, P Claudepierre, Y Bouhnik, A Amiot
BACKGROUND: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity. AIM: To assess effectiveness of vedolizumab for EIM in patients with inflammatory bowel disease (IBD) in a large real-life experience cohort. METHODS: Between June and December 2014, 173 patients with Crohn's disease and 121 with ulcerative colitis were treated with vedolizumab. Patients were followed until week 54...
December 18, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29250800/postoperative-outcomes-in-vedolizumab-treated-crohn-s-disease-patients-undergoing-major-abdominal-operations
#5
A L Lightner, N P McKenna, C S Tse, L E Raffals, E V Loftus, K L Mathis
BACKGROUND: Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. AIM: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy...
December 18, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29250117/ustekinumab-and-vedolizumab-dual-biologic-therapy-in-the-treatment-of-crohn-s-disease
#6
Eddie Y Liu, Dustin E Loomes
We present a case of refractory ileocolonic Crohn's disease in a 27-year-old female treated with dual ustekinumab and vedolizumab biologic therapy. She had mucosal healing for the first time in 13 years after a 10-month treatment of ustekinumab overlapped with 6 months of vedolizumab. No side effects were observed during the 6 months of dual biologic therapy. Short-term dual biologic therapy may be considered as a treatment option for induction of remission in refractory cases of Crohn's disease.
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/29223444/association-of-vedolizumab-level-anti-drug-antibodies-and-%C3%AE-4%C3%AE-7-occupancy-with-response-in-patients-with-inflammatory-bowel-diseases
#7
Bella Ungar, Uri Kopylov, Miri Yavzori, Ella Fudim, Orit Picard, Adi Lahat, Daniel Coscas, Matti Waterman, Ola Haj-Natour, Noam Orbach-Zingboim, Ren Mao, Minhu Chen, Yehuda Chowers, Rami Eliakim, Shomron Ben-Horin
BACKGROUND & AIMS: There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We performed a prospective study of patients with inflammatory bowel diseases (IBD) treated with vedolizumab to determine serum drug concentrations, formation of anti-vedolizumab antibodies (AVAs), and integrin α4β7 saturation. METHODS: We performed a prospective study of 106 patients with IBD (67 with Crohn's disease and 39 with ulcerative colitis) treated with vedolizumab from September 2014 through March 2017 at 2 tertiary medical centers in Israel...
December 6, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29223139/novel-treatments-for-inflammatory-bowel-disease
#8
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has led to the development of targeted therapies and has unlocked a new era in IBD treatment. The development of treatment options aimed at a variety of pathological mechanisms offers new hope for customized therapies. Beyond anti-tumor necrosis factor agents, selective lymphocyte trafficking inhibitors have been proposed as potent drugs for IBD. Among these, vedolizumab has recently been approved for both Crohn's disease and ulcerative colitis...
December 11, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29192397/ustekinumab-for-treating-moderately-to-severely-active-crohn-s-disease-after-prior-therapy-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#9
Robert Hodgson, Matthew Walton, Mousumi Biswas, Teumzghi Mebrahtu, Nerys Woolacott
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to submit evidence on the clinical and cost effectiveness of their drug ustekinumab, an interleukin-12/23 inhibitor, for treating moderate-to-severe active Crohn's disease (CD). The Centre for Reviews and Dissemination (CRD) and Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the independent Evidence Review Group (ERG)...
November 30, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29182760/expression-patterns-of-tnf%C3%AE-madcam1-and-stat3-in-intestinal-and-skin-manifestations-of-inflammatory-bowel-disease
#10
Stephan R Vavricka, Jose A Galván, Heather Dawson, Alex Soltermann, Luc Biedermann, Michael Scharl, Alain M Schoepfer, Gerhard Rogler, Mareike B Prinz Vavricka, Luigi Terracciano, Alexander Navarini, Inti Zlobec, Alessandro Lugli, Thomas Greuter
Background: Pathogenesis of cutaneous extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms. The role of other biologics such as anti-integrins or JAK-inhibitors is not yet clear. Methods: We performed immunohistochemistry for TNFα, NFκB, STAT1/STAT3, MAdCAM1, CD20/68, caspase 3/9, IFNγ, Hsp-27/70 on 240 intestinal (55 controls, 185 IBD) and 64 skin biopsies (11 controls, 18 Erythema nodosum (EN), 13 Pyoderma gangenosum (PG), 22 psoriasis)...
November 22, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29162338/interstitial-nephritis-secondary-to-vedolizumab-treatment-in-crohn-disease-and-safe-rechallenge-using-steroids-a-case-report
#11
Elodie Bailly, Florent Von Tokarski, Frédérique Beau-Salinas, Laurence Picon, Elodie Miquelestorena-Standley, Geoffroy Rousseau, Annie-Pierre Jonville-Bera, Jean-Michel Halimi
Vedolizumab is a gut-selective humanized monoclonal antibody that binds selectively to the α4 β7 integrin and acts as a lymphocyte-homing antagonist. It is indicated in ulcerative colitis and Crohn disease. We report a case of acute interstitial nephritis following vedolizumab infusion in a 55-year-old white woman treated for severe Crohn disease resistant to several therapies. Other kidney disease causes were ruled out. Glucocorticoids were administrated, leading to full renal recovery. In the absence of other therapeutic options, vedolizumab was re-administered along with transient corticosteroids; this treatment was well tolerated...
November 18, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29140943/antibodies-toward-vedolizumab-appear-from-the-first-infusion-onward-and-disappear-over-time
#12
Sumin Bian, Erwin Dreesen, Ho Tsun Tang, Griet Compernolle, Miet Peeters, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
BACKGROUND: Vedolizumab (VDZ) has been approved for the treatment of patients with moderate-to-severe Crohn's disease and ulcerative colitis. The GEMINI trials reported a low prevalence of anti-VDZ antibodies (AVA). However, the AVA assays used in GEMINI were drug sensitive, resulting in a possible underestimation of the rate of AVA formation. This study aimed to monitor immunogenicity of VDZ in a real-life cohort using a drug-resistant AVA assay. METHODS: Using a combination of VDZ/AVA complex precipitation and acid dissociation, a drug-resistant assay for AVA detection in the presence of high VDZ concentrations has been developed and analytically validated...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29139091/pharmacological-approach-to-the-management-of-crohn-s-disease-patients-with-perianal-disease
#13
REVIEW
Fernando Bermejo, Iván Guerra, Alicia Algaba, Antonio López-Sanromán
Perianal localization of Crohn's disease involves significant morbidity, affects quality of life and results in an increased use of healthcare resources. Medical and surgical therapies contribute to its management. The objective of this review is to address the current understanding in the management of perianal Crohn's disease, with the main focus in reviewing pharmacological therapies, including stem cells. In complex fistulas, once local sepsis has been controlled by surgical drainage and/or antibiotics, anti-TNF drugs (infliximab, adalimumab) are the first-line therapy, with or without associated immunomodulators...
January 2018: Drugs
https://www.readbyqxmd.com/read/29115855/an-indirect-comparison-of-ustekinumab-and-vedolizumab-in-the-therapy-of-tnf-failure-crohn-s-disease-patients
#14
Paweł Kawalec, Paweł Moćko
AIM: An indirect comparison of ustekinumab versus vedolizumab in patients with active moderate-to-severe Crohn's disease who were nonresponsive or intolerant to previous TNF-antagonist therapy. METHODS: A systematic review was performed in Medline via PubMed, Embase, Cochrane Library, until 30 April 2017. Inclusion criteria were: randomized controlled trials, patients treated for Crohn's disease, ustekinumab or vedolizumab therapy. Included trials were critically appraised and afterward indirect comparison by Bucher was conducted; the manuscript was prepared in accordance to the PRISMA requirements...
November 8, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29077833/vedolizumab-in-ibd-lessons-from-real-world-experience-a-systematic-review-and-pooled-analysis
#15
Tal Engel, Bella Ungar, Diana E Yung, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov
Background: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). Several real-world experience (RWE) studies with VDZ were published to date. The aim of this systematic review was to summarize the available real-life experience with VDZ. Methods: We performed a systematic review of the available RWE studies of VDZ in CD and UC. We performed a pooled analysis of the available efficacy and safety data for induction and maintenance treatment in adult cohorts...
October 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28974896/access-to-biologicals-in-crohn-s-disease-in-ten-european-countries
#16
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji, Crohn's Disease Research Group
AIM: To analyze access (availability, affordability and acceptability) to biologicals for Crohn's disease (CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development. METHODS: A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals...
September 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28973005/a-systematic-review-of-cost-effectiveness-studies-comparing-conventional-biological-and-surgical-interventions-for-inflammatory-bowel-disease
#17
REVIEW
Nadia Pillai, Mark Dusheiko, Bernard Burnand, Valérie Pittet
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic burden on health systems worldwide. The treatment landscape is complex with multiple strategies to induce and maintain remission while avoiding long-term complications. The extent to which rising treatment costs, due to expensive biologic agents, are offset by improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD...
2017: PloS One
https://www.readbyqxmd.com/read/28961959/the-expanding-therapeutic-armamentarium-for-inflammatory-bowel-disease-how-to-choose-the-right-drug-s-for-our-patients
#18
Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, Reena Khanna, Geert D'Haens, William J Sandborn, Silvio Danese, Vipul Jairath, Brian G Feagan
The therapeutic landscape for inflammatory bowel disease (IBD) is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD...
August 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28953016/nodular-vasculitis-in-a-patient-with-crohn-s-disease-on-vedolizumab
#19
Delila Pouldar, Ashley Elsensohn, Francesca Ortenzio, Jessica Shiu, Michael McLeod, Sébastien de Feraudy
Erythema induratum (EI), or nodular vasculitis (NV), is a type of panniculitis that is often associated with vasculitis affecting various-sized veins, venules, and arteries in reaction to various causative factors. Historically, EI was highly linked to tuberculosis, but in 1946, Montgomery first proposed the term NV to describe cases of EI not associated with tuberculosis. Only 2 reports of NV associated with inflammatory bowel disease have been reported in the literature. The authors report a 60-year-old woman with Crohn's disease presenting with exacerbation of NV in the setting of vedolizumab therapy...
September 20, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28858074/efficacy-of-combination-vedolizumab-and-ustekinumab-for-refractory-crohn-s-disease
#20
Kayci Huff-Hardy, Mai Bedair, Rebecca Vazquez, Ezra Burstein
No abstract text is available yet for this article.
August 29, 2017: Inflammatory Bowel Diseases
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"